Open AccessThe Potential Role of Angiogenic Osteoclast Inhibition in the Occurrence of Bisphosphonate-related Osteonecrosis of the Jaw
Author(s) -
Ntep David Bienvenue Ntep,
Ernest Kenna,
Siafa Antoine Bola,
Messanga Charles Bengondo,
Otolaryngology Ophtamology
Publication year - 2020
Language(s) - English
DOI - 10.46619/crds.2020.1-1004
Subject(s) - bisphosphonate , osteoclast , osteonecrosis of the jaw , angiogenesis , medicine , pathophysiology , bone remodeling , diphosphonates , bone resorption , cancer research , bone density conservation agents , osteoporosis , bone density , receptor
Bisphosphonate-related osteonecrosis of the jaw is a serious complication of systemic bisphosphonate administration, the mechanism of which remains unclear. Many hypotheses regarding pathophysiology are discussed, including the most commonly cited: suppression of bone remodeling and suppression of angiogenesis, but none of these would explain all the unique features of bisphosphonaterelated jaw osteonecrosis. Bisphosphonates are potent inhibitors of osteoclasts, and recent studies have shown that osteoclasts are important for bone angiogenesis. Therefore, we hypothesize that bisphosphonates inhibit osteoclastic stimulation of angiogenesis, thereby contributing to the occurrence of osteonecrosis of the jaws. This theory would partially explain the pathophysiology of bisphosphonate-related osteonecrosis of the jaw to the unfathomable.